Generic Medicine Info
Indications and Dosage
Facilitate SC/IM injections
Adult: 1500 units directly added to the inj.

Adjunct in hypodermoclysis
Adult: 1500 units for every 500-1000 ml of fluid for SC admin.

Aid in the diffusion of local anaesthetic in ophthalmology
Adult: 15 units/ml of local anaesthetic solution.

Aid in the dispersal of extravasated fluids or blood
Adult: 1500 units in 1 ml of water for inj or normal saline is injected into the affected area.
Adjunct in hypodermoclysis: Physical incompatibility has been reported with heparin and adrenaline, frusemide, benzodiazepines and phenytoin.
Hypersensitivity, malignancy. Direct application to the cornea, reduction of swelling of bites or stings. Inj into or around infected area. IV admin; unexplained premature labour.
Special Precautions
Impaired renal function. Infants, elderly. Patients with infections. Pregnancy, lactation.
Adverse Reactions
Urticaria, occasional severe allergy.
Potentially Fatal: Hypersensitivity and anaphylaxis.
IM/Intradermal/Intraocular/Parenteral/SC: C
Symptoms include hypotension, tachycardia, headache and generalised skin flushing. Other complications may include myocardial ischaemia and subsequent MI, cardiac arrhythmia and profound shock. Treatment is supportive and symptomatic.
Drug Interactions
Action potentiated by urokinase especially in the treatment of MI. May increase absorption and toxicity of local anaesthetics. Heparin, salicylates and NSAIDs may inhibit the spreading action and efficacy of hyaluronidase.
Description: Hyaluronidase is an enzyme which reduces the viscosity of ground substance, thus making the tissues more permeable to injected fluids. It facilitates distribution and absorption of locally injected substances. It also promotes resorption of excess fluids and extravasated blood in the tissues.
Refrigerate at 2-8°C.
MIMS Class
Other Therapeutic Products
Disclaimer: This information is independently developed by MIMS based on Hyaluronidase from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in